Advertisement
CAH vs MCK
Which Stock Would AI Choose? Cardinal Health (CAH) vs. McKesson (MCK) Stock Comparison
Key Takeaways
- CAH has dramatically outperformed MCK over the past 12 months, gaining roughly 43% versus approximately 10% for McKesson, though both operate in the same pharmaceutical distribution industry.
- Both companies delivered strong double-digit earnings growth in their most recent quarters, driven by specialty pharmaceutical demand, oncology platform expansion, and increased prescription volumes.
- MCK remains the larger competitor by market capitalization at approximately $92 billion versus Cardinal Health's roughly $56 billion, with significantly higher annual revenue.
- Cardinal Health's specialty-focused transformation — including the Solaris Health acquisition in urology — has generated stronger recent earnings momentum and upward guidance revisions.
- McKesson's planned separation of its Medical-Surgical Solutions segment represents a major strategic catalyst that could unlock shareholder value but introduces execution uncertainty in the near term.
- Both stocks trade at attractive forward P/E (price-to-earnings) ratios under 22x, with analysts maintaining broadly constructive outlooks on both names.
Introduction
Cardinal Health and McKesson Corporation are two of the three dominant players in the U.S. pharmaceutical wholesale and distribution market — an oligopoly that, together with Cencora, controls more than 90% of domestic drug distribution. For investors evaluating healthcare sector exposure, comparing these two stocks offers a window into how scale, strategic focus, and capital allocation decisions shape relative performance. While both companies benefit from the same secular tailwinds — aging demographics, rising prescription volumes, and expanding specialty drug pipelines — their recent stock trajectories have diverged meaningfully. This comparison examines what is driving each company, how their market positioning differs, and which stock appears better positioned in the current environment.
CAH Overview and Recent Performance
CAH, headquartered in Dublin, Ohio, is one of three leading pharmaceutical wholesalers in the United States, distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospital networks, and healthcare providers. The company also manufactures medical products and operates higher-margin growth businesses including at-Home Solutions, Nuclear & Precision Health Solutions, and OptiFreight Logistics. In recent months, Cardinal Health has delivered standout stock performance, gaining more than 70% in calendar 2025 and adding further gains in 2026. Its most recent quarterly results showed revenue of $65.63 billion, representing 18.8% year-over-year growth, with adjusted earnings per share (EPS) of $2.63 that comfortably beat analyst estimates. All five operating segments posted double-digit profit growth, underscoring broad-based operational execution. Management raised full-year EPS guidance, reflecting confidence in sustained specialty pharmaceutical momentum. The acquisition of Solaris Health, a leading urology MSO (Management Services Organization) with over 750 providers, further advances Cardinal Health's multi-specialty growth strategy. Barclays initiated coverage with an Overweight rating and a $243 price target in December 2025, citing the company's ongoing transformation toward higher-margin healthcare services.
MCK Overview and Recent Performance
MCK, headquartered in Irving, Texas, is the largest U.S. pharmaceutical distributor by revenue, with operations spanning North American Pharmaceutical distribution, Oncology & Multispecialty platforms, Prescription Technology Solutions, and Medical-Surgical Solutions. The company generated fiscal 2025 revenue of approximately $359 billion, with adjusted EPS of $33.05. In recent quarters, McKesson has continued to execute well operationally: its fiscal 2026 third-quarter results showed revenue of $106.2 billion (11% growth) and adjusted EPS of $9.34 (16% growth), prompting management to raise full-year EPS guidance to $38.80 to $39.20. However, despite solid earnings delivery, McKesson's stock has underperformed Cardinal Health meaningfully over the past year, rising approximately 10% compared to CAH's 43% gain. MCK shares have also pulled back roughly 23% from their 52-week high near $999 reached in March 2026. A major strategic development is McKesson's announced intention to separate its Medical-Surgical Solutions segment into an independent publicly traded company — a move designed to sharpen strategic focus on higher-growth, higher-margin oncology and biopharma services. The company also completed its exit from Europe with the divestiture of its Norwegian businesses in January 2026.
Trending AI Robots
For traders and investors seeking a data-driven edge in evaluating stocks like CAH and MCK, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate diverse market conditions. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest real-time performance and adaptability to current market dynamics earn a place in this featured section. Each bot operates with distinct trading styles, timeframes, and strategies — ranging from swing trading and trend following to pattern recognition and momentum-based approaches — with track records featuring win rates, Sharpe ratios, and trade counts that investors can evaluate. The curated selection simplifies discovery by highlighting bots whose algorithms align with prevailing market regimes. Exploring the Trending AI Robots page can help traders identify AI-driven strategies that complement their own analysis of healthcare distribution stocks.
Head-to-Head Comparison
While both CAH and MCK operate fundamentally similar pharmaceutical wholesale models, several contrasts define their investment profiles. Scale and revenue: McKesson generates roughly $403 billion in trailing twelve-month revenue versus Cardinal Health's approximately $251 billion, giving MCK significantly larger absolute cash flows. Profitability and margins: McKesson's net margin of approximately 1.18% exceeds Cardinal Health's roughly 0.62%, reflecting operational efficiencies at scale. However, CAH's higher-margin specialty growth businesses are expanding faster, with its "Other" segment posting 37% revenue growth in the most recent fiscal quarter. Momentum: Cardinal Health holds a clear advantage in recent stock performance, up roughly 17% year-to-date in 2026 versus MCK's slight decline, driven by superior earnings revisions and more aggressive guidance raises. Strategic catalysts: McKesson's planned Medical-Surgical spin-off could unlock value but introduces near-term complexity; Cardinal Health's Solaris integration and multi-specialty MSO (Management Services Organization) buildout represent more incremental, execution-driven catalysts. Risk factors: Both face drug pricing regulatory risk and GLP-1 (glucagon-like peptide-1) drug pricing dynamics, though McKesson's larger exposure to retail national accounts may create additional sensitivity. Valuation: McKesson trades at a forward P/E of approximately 19-21x, while Cardinal Health trades at roughly 22-23x — a premium that reflects CAH's stronger growth trajectory and momentum.
Tickeron AI Verdict
Based on observable trend data and relative positioning, Tickeron's AI-driven analysis would likely favor CAH over MCK in the current market environment. Cardinal Health's superior 12-month price momentum, consistent earnings beats, aggressive upward guidance revisions, and successful expansion into higher-margin specialty healthcare services create a compelling trend profile. While McKesson's larger scale, higher absolute profitability, and strategic portfolio restructuring via the Medical-Surgical separation present meaningful long-term potential, the near-term trend signals — including price underperformance relative to peers and a 23% drawdown from 52-week highs — suggest less favorable momentum. The AI assessment emphasizes probabilistic outcomes: Cardinal Health's more consistent upward trajectory across multiple timeframes implies a higher probability of continued relative strength, though both companies remain fundamentally sound operators in an essential industry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAH is a Hold and MCK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CAH’s FA Score shows that 2 FA rating(s) are green whileMCK’s FA Score has 2 green FA rating(s).
- CAH’s FA Score: 2 green, 3 red.
- MCK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CAH’s TA Score shows that 4 TA indicator(s) are bullish while MCK’s TA Score has 6 bullish TA indicator(s).
- CAH’s TA Score: 4 bullish, 4 bearish.
- MCK’s TA Score: 6 bullish, 4 bearish.
Price Growth
CAH (@Medical Distributors) experienced а -0.21% price change this week, while MCK (@Medical Distributors) price change was -0.06% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -2.45%. For the same industry, the average monthly price growth was +1.07%, and the average quarterly price growth was -9.41%.
Reported Earning Dates
CAH is expected to report earnings on Aug 11, 2026.
MCK is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Medical Distributors (-2.45% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| CAH | MCK | CAH / MCK | |
| Capitalization | 53.4B | 98.5B | 54% |
| EBITDA | 3.27B | 7.18B | 46% |
| Gain YTD | 11.752 | 2.711 | 433% |
| P/E Ratio | 34.81 | 21.91 | 159% |
| Revenue | 251B | 403B | 62% |
| Total Cash | N/A | 3.98B | - |
| Total Debt | 8.92B | 8.61B | 104% |
CAH | MCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 17 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 44 | 47 | |
P/E GROWTH RATING 1..100 | 22 | 72 | |
SEASONALITY SCORE 1..100 | 30 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCK's Valuation (13) in the Medical Distributors industry is somewhat better than the same rating for CAH (70). This means that MCK’s stock grew somewhat faster than CAH’s over the last 12 months.
CAH's Profit vs Risk Rating (5) in the Medical Distributors industry is in the same range as MCK (17). This means that CAH’s stock grew similarly to MCK’s over the last 12 months.
CAH's SMR Rating (100) in the Medical Distributors industry is in the same range as MCK (100). This means that CAH’s stock grew similarly to MCK’s over the last 12 months.
CAH's Price Growth Rating (44) in the Medical Distributors industry is in the same range as MCK (47). This means that CAH’s stock grew similarly to MCK’s over the last 12 months.
CAH's P/E Growth Rating (22) in the Medical Distributors industry is somewhat better than the same rating for MCK (72). This means that CAH’s stock grew somewhat faster than MCK’s over the last 12 months.
| CAH | MCK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 42% | 2 days ago 39% |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 38% |
| Momentum ODDS (%) | 2 days ago 45% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 41% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 44% | 2 days ago 39% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 68% |
| Advances ODDS (%) | 2 days ago 66% | 2 days ago 65% |
| Declines ODDS (%) | 6 days ago 43% | 4 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 45% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 73% |
Advertisement
CAH and
Correlation & Price change
A.I.dvisor indicates that over the last year, CAH has been closely correlated with MCK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAH jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To CAH | 1D Price Change % | ||
|---|---|---|---|---|
| CAH | 100% | +0.91% | ||
| MCK - CAH | 68% Closely correlated | +1.99% | ||
| COR - CAH | 57% Loosely correlated | +1.58% | ||
| FOCL - CAH | 9% Poorly correlated | -0.99% | ||
| YI - CAH | 6% Poorly correlated | -4.85% | ||
| COSM - CAH | 1% Poorly correlated | +0.05% | ||
More | ||||